Both compounds exhibit a preference for ACAT1/SOAT1 over ACAT2/SOAT2 and both have passed phase 1 clinical safety tests as anti-atherosclerosis therapeutics; reviewed in [66]. The gene discussed is SOAT1; the disease is atherosclerosis.